ACAD ACADIA Pharmaceuticals Inc.

50.48
+6.2  (+14%)
Previous Close 44.28
Open 52.98
Price To Book 11.27
Market Cap 7,775,205,322
Shares 154,025,462
Volume 7,432,698
Short Ratio
Av. Daily Volume 1,468,972
Stock charts supplied by TradingView

NewsSee all news

  1. ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

    - Pimavanserin met the primary endpoint in the study, significantly reducing the risk of relapse of psychosis by 2.8 fold (Hazard Ratio (HR)=0.353, one-sided p=0.0023) - Pimavanserin met the key secondary endpoint in

  2. ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia

    - ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced positive

  3. ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting on December 4, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a

  4. ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to

  5. ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - CLARITY-2
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 data released November 25, 2019. Primary endpoint met. Key secondary missed. Further pivotal trial to be initiated 2H 2020.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 3 trial stopped early after meeting primary endpoint - September 9, 2019. Data presented at CTAD meeting December 4, 2019 noted HR =0.353, one-sided p=0.0023.
Pimavanserin - Harmony
Alzheimer’s disease psychosis
Phase 3 trial initiation announced October 30, 2019.
Trofinetide
Rett Syndrome

Latest News

  1. ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

    - Pimavanserin met the primary endpoint in the study, significantly reducing the risk of relapse of psychosis by 2.8 fold (Hazard Ratio (HR)=0.353, one-sided p=0.0023) - Pimavanserin met the key secondary endpoint in

  2. ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia

    - ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced positive

  3. ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting on December 4, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a

  4. ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to

  5. ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

  6. ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

    - 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare

  7. ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress

    — Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that based

  8. ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer's Disease (CTAD) 2019 Meeting

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral

  9. ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today

  10. ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

    - Pimavanserin as an adjunctive treatment for patients with MDD showed significant overall improvement in HAMD-17 total score compared to placebo - Phase 3 CLARITY program initiated in April 2019 ACADIA

  11. ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson's Disease and Movement Disorders

    - Pimavanserin as monotherapy or adjunct to SSRI/SNRI therapies significantly improved depression symptoms for Parkinson's patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced positive results from an

  12. ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

  13. ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings

    — New data presented at the International Congress of Parkinson's Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson's disease and depression — New data

  14. ACADIA Pharmaceuticals Prices Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

  15. ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

  16. Thinking about buying stock in Acadia Pharmaceuticals, Aurora Cannabis, Bank of America, SINTX Technologies, or AT&T?

    NEW YORK, Sept. 9, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ACB, BAC, SINT, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

  17. ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis

    - Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be the first FDA-approved

  18. ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today